Role of Synergistic Action of PAF and Kinin in Bacterial Endotoxin-Induced Hypotension in Rats

  • Sachiko Oh-Ishi
  • Hideki Ishida
  • Akinori Ueno
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 416)


Involvement of PAF and kinin in the endotoxin (LPS)-induced hypotension was examined in the rat strains, Brown Norway (B/N);Kitasato (Normal) and B/N-Kitasato rats, intravenous injection of 10 mg/kg LPS caused a hypotension composed on two phases (15 min and 70 min after LPS injection). However in the kininogen-deficient B/N-Katholiek rats, LPS induced only the second phase. Pretreatment with bradykinin (BK) antagonist, Hoe 140 suppressed LPS-induced hypotension of normal rats to the level of Katholiek rats. TCV 309, a PAF-antagonist, suppressed the LPS-hypotension almost completely in the both strains. The reason why the PAF-antagonist showed almost complete inhibition, could be explained by a synergism. Because concomitant injection of a small amount of BK with PAF caused potentiation of the effect of the PAF action. These results suggest that formation of endogenous BK contributes mainly to the 1st phase of LPS-hypotension, and PAF contributes to the both phases, by either direct and synergistic actions.


Synergistic Action Hypotensive Response Pentobarbital Sodium Anesthesia Bradykinin Antagonist Concomitant Injection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hock, F. J., Wirth, K., Albus, U., Linz, W., Gerhards, H. J., Wiemer, G., Henke, S. T., Breiphol, G., Konig, W., Knolle, L. and Scholkens, B. A.: Br. J. Pharmacol., 102, 769–773 (1991).PubMedCrossRefGoogle Scholar
  2. 2.
    Terashita, Z.. Kawamura, M., Takatani, M., Tsushima, S.: lmura, Y., and Nishikawa, K.: J. Pharmacol. Exp. Therap., 260, 748–755 (1991).Google Scholar
  3. 3.
    Oh-Ishi, S., Satoh, K., Hayashi. 1., Yamazaki, K. and Nakano, T.; Thrombosis Res., 28, 143–147 (1982).CrossRefGoogle Scholar
  4. 4.
    Weipert, J.. Hoffmann, H., Siebeck, M. and Whalley. E. T.: Br. J. Pharmacol., 94, 282–284 (1988).CrossRefGoogle Scholar
  5. 5.
    Wilson, D. D., Garaviella, L., Kuhn, W., Togo, J., Burch, R. M. and Sterenka, L. R.: Circ. Shock 27, 93–101 (1989).PubMedGoogle Scholar
  6. 6.
    Terashita, Z., Tsushima, S.. Yoshioka, Y, Nomura, H., Inada, Y. and Nishikawa. K.: Life Sci., 32, 1975–1982 (1982).Google Scholar
  7. 7.
    Parratt, J. R. and Sturgess, R. M.: Br. J. Pharmacol., 53 485–488 (1975).PubMedCrossRefGoogle Scholar
  8. 8.
    Thiemermann, C. and Vane, J. R.: Br. J. Pharmacol., 182, 591–595 (1990).Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Sachiko Oh-Ishi
    • 1
  • Hideki Ishida
    • 1
  • Akinori Ueno
    • 1
  1. 1.Department of Pharmacology School of Pharmaceutical SciencesKitasato UniversityShirokane, Minato-ku, Tokyo 108Japan

Personalised recommendations